Amy Melsaether, M.D., is Chief Medical Officer at Graviton Bioscience Corporation. She brings nearly two decades of experience in academia and industry to her position. Dr. Melsaether most recently served as SVP of Clinical Research at Equilibre Biopharmaceuticals from 2020-2022. Prior, Dr. Melsaether was Associate Professor of Radiology at Mt. Sinai (2018-2021) and Associate and Assistant Professor of Radiology at NYU (2010-2018). At NYU, Dr. Melsaether pioneered work on PET/MRI in breast cancer and on optimized breast MRI. She served in multiple leadership roles, was awarded Fellowship in the Society of Breast Imaging, developed the institutional breast imaging curriculum, and served on multiple internal and external committees. She has mentored extensively, published more than 30 articles in peer-reviewed journals, served as a reviewer for leading journals, and has presented her work and been invited to talks globally.

Dr. Melsaether earned her honors B.S. in biochemistry, molecular biology, and English from the University of Wisconsin, Madison, and her M.D. from the David Geffen School of Medicine at UCLA. Dr. Melsaether was a Howard Hughes Fellow in Immunology at the NIH from 2001-2002 and was awarded the Howard Hughes Medical Institute Scientist-Scholar Award in 2002.